Latest news with #orthopedic
BBC News
2 days ago
- Health
- BBC News
Warwickshire surgeon retires after helping 15,000 patients
A hospital trust's longest serving orthopedic consultant is retiring after performing 15,000 joint replacements over more than three decades. Stephen Young joined the South Warwickshire University NHS Foundation Trust (SWFT) in 1989 and played a crucial role in setting up its orthopaedic unit. He temporarily stepped down from his role before the pandemic in preparation for retirement, however he returned to support the trust after a mobile theatre was installed to increase the number of operations that could be carried out. Tamara Harries, general manager for orthopaedics at SWFT, said many of Mr Young's patients "owed their mobility and quality of life to his expert hands". Mr Young performed nearly 1,000 hip replacements in the last three also helped to set up the South Warwickshire Accelerated Transfer Team (SWATT) service, which oversees the entire patient journey, from when they are added to a waiting list, to being back at home fully recovered. A spokesperson for the trust credited SWATT for helping the trust to become "one of the most efficient orthopaedic units in the country". Lasting legacy Glen Burley, foundation group chief executive, said thousands of patients, staff and trainees had benefited from Mr Young's skills."We will all miss his leadership and his calm, caring and efficient approach," Mr Burley Young is set to retire next month, however he leaves a lasting legacy. A bi-annual community event, the Sky Walk, where former patients walk alongside the trust's orthopedic team, was previously named in Mr Young's honour. It continues to raise money for the unit that he helped to establish. Follow BBC Coventry & Warwickshire on BBC Sounds, Facebook, X and Instagram.
Associated Press
3 days ago
- Business
- Associated Press
Movora Becomes Exclusive Distributor of Aesculap Surgical Power Systems in North America
St. Augustine, Florida--(Newsfile Corp. - July 21, 2025) - As of Tuesday, May 20, 2025, Movora is proud to announce it has entered into an exclusivity agreement with Aesculap, a division of B. Braun VetCare, to become the sole distributor of Aesculap Surgical Power Systems and power accessories in the United States and Canada. This partnership further strengthens Movora's commitment to providing premium orthopedic and surgical solutions to veterinary professionals across North America. By securing exclusive distribution rights, Movora will ensure enhanced access to Aesculap's innovative power systems, reinforcing its role as a leader in the veterinary surgical space. 'Movora has a long-standing relationship with Aesculap Surgical Power products as part of our core orthopedic business, and we are very excited about the exclusive partnership in North America, our largest market,' said Guy Spörri, CEO of Movora. 'This agreement represents a significant step forward in our mission to support veterinary professionals with world-class surgical technologies.' Achim Ott, Export Sales Manager at Aesculap/B. Braun VetCare, added: 'We are very much looking forward to our continued cooperation and hope for further successful business together.' The agreement officially designates Movora as the exclusive North American distributor of Aesculap Surgical Power and accessories, ensuring streamlined service, consistent availability, and expert support for customers across the U.S. and Canada. Non-Movora Aesculap Power Customers will utilize Movora for all Aesculap Power Equipment Repairs moving forward. Please visit for more information and to get started. For more information, visit Media Contacts: Korrie Wilhelm, VP Global MarCom, Brand Strategy & Ecommerce Movora Achim Ott, Export Sales Manager BBraun VetCare/Aesculap [email protected] To view the source version of this press release, please visit
Yahoo
3 days ago
- Business
- Yahoo
Movora Becomes Exclusive Distributor of Aesculap Surgical Power Systems in North America
St. Augustine, Florida--(Newsfile Corp. - July 21, 2025) - As of Tuesday, May 20, 2025, Movora is proud to announce it has entered into an exclusivity agreement with Aesculap, a division of B. Braun VetCare, to become the sole distributor of Aesculap Surgical Power Systems and power accessories in the United States and Canada. This partnership further strengthens Movora's commitment to providing premium orthopedic and surgical solutions to veterinary professionals across North America. By securing exclusive distribution rights, Movora will ensure enhanced access to Aesculap's innovative power systems, reinforcing its role as a leader in the veterinary surgical space. "Movora has a long-standing relationship with Aesculap Surgical Power products as part of our core orthopedic business, and we are very excited about the exclusive partnership in North America, our largest market," said Guy Spörri, CEO of Movora. "This agreement represents a significant step forward in our mission to support veterinary professionals with world-class surgical technologies." Achim Ott, Export Sales Manager at Aesculap/B. Braun VetCare, added: "We are very much looking forward to our continued cooperation and hope for further successful business together." The agreement officially designates Movora as the exclusive North American distributor of Aesculap Surgical Power and accessories, ensuring streamlined service, consistent availability, and expert support for customers across the U.S. and Canada. Non-Movora Aesculap Power Customers will utilize Movora for all Aesculap Power Equipment Repairs moving forward. Please visit for more information and to get started. For more information, visit Media Contacts:Korrie Wilhelm, VP Global MarCom, Brand Strategy & Achim Ott, Export Sales ManagerBBraun VetCare/ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
7 days ago
- Business
- Yahoo
What You Need To Know Ahead of Zimmer Biomet's Earnings Release
Warsaw, Indiana-based Zimmer Biomet Holdings, Inc. (ZBH) designs, manufactures, and markets effective, innovative solutions that support orthopedic surgeons and clinicians in restoring mobility, alleviating pain, and improving the quality of life for patients worldwide. With a market cap of $18.6 billion, it operates in more than 25 countries across the globe and sells products in more than 100 countries. Zimmer is expected to release its Q2 earnings before the markets open on Thursday, Aug. 7. Ahead of the event, analysts expect it to report a profit of $1.99 per share, down 1% from $2.01 per share reported in the year-ago quarter. While the company has missed the Street's bottom-line estimates once over the past four quarters, it has surpassed the estimates on three other occasions. More News from Barchart Dear Google Stock Fans, Mark Your Calendars for July 23 Retirement Ready: 3 Dividend Stocks to Set and Forget Dear UnitedHealth Stock Fans, Mark Your Calendars for July 29 Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For fiscal 2025, Zimmer is expected to report an EPS of $7.95, marginally down from $8 in fiscal 2024. In fiscal 2026, its EPS is expected to rebound 2.9% year-over-year to $8.18. ZBH stock has plunged 12.3% over the past 52 weeks, lagging behind the Health Care Select Sector SPDR Fund's (XLV) 10.4% drop and the S&P 500 Index's ($SPX) 10.5% gains during the same time frame. Despite delivering better-than-expected financials, ZBH stock plunged 11.6% in the trading session following the release of its Q1 results on May 5. The company's performance was notably impacted due to currency headwinds. However, its net sales inched up 1.1% year-over-year to $1.9 billion and surpassed the Street's expectations by a thin margin. Meanwhile, its adjusted EPS dropped 6.7% year-over-year to $1.81, but surpassed the consensus estimates by 2.8%. Furthermore, the company improved its full-year topline guidance. However, it reduced its full-year EPS guidance from the previously announced $8.15 - $8.35 range to $7.90 - $8.10, which unsettled investor confidence. The stock maintains a consensus 'Moderate Buy' rating overall. Of the 27 analysts covering the ZBH stock, opinions include eight 'Strong Buys,' two 'Moderate Buys,' 15 'Holds,' and two 'Strong Sells.' Its mean price target of $107.04 suggests a 13.6% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
National Post
16-07-2025
- Health
- National Post
Nanochon Announces Health Canada Approval for First in Human Investigation
Article content WASHINGTON — Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada Approval for their first in human clinical trial. Article content The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with Sports Medicine Specialists, Drs. Joel Lobo, Kajeandra Ravichandiran and Marcin Kowalczuk as Sub-Investigators, at the Durham Bone & Joint Specialists (DBJS), located in Ontario, Canada. Dr. Fathi Abuzgaya is an orthopedic surgeon by training and an esteemed researcher with a track record over the last 25 years, leading +600 clinical trials in all phases and therapeutic areas. Article content 'Our team is delighted that we are the first center to start enrolling participants for the Chondrograft™ study, which represents a novel, minimally invasive treatment for patients with loss of or damaged knee cartilage,' Dr. Abuzgaya commented. 'DBJS is a multidisciplinary musculoskeletal center providing non-operative and operative treatments with accessibility to a variety of sub-specialties. Our study site with dedicated researchers enables greater, more efficient patient recruitment for clinical research and we are privileged to support Nanochon.' Article content The Nanochon Chondrograft™ System is being evaluated in a prospective, 10 patient, early feasibility study for use in knee cartilage restoration in eligible patients between 22 and 60 years of age having femoral condyle and /or trochlea articular cartilage lesions who have failed conservative therapy, in addition to meeting other criteria. The study is designed to assess the safety and performance of Chondrograft™, and procedural goals include regrowth of the cartilage-bone matrix, improvement in knee function and pain, and delayed need for arthroplasty. Article content 'Achieving Health Canada approval allows us to gain the clinical data needed to take a giant step forward towards design and execution of a large pivotal North American study,' said Ben Holmes, CEO of Nanochon. 'We have the utmost confidence in Dr. Abuzgaya and his clinical team at DBJS to help us recruit the right patients and execute the trial protocol that we have so carefully designed.' Article content While the first in human trial will take place in Canada, this represents just the first step towards a larger clinical program. Article content 'Thousands of patients with chondral defects, that may evolve to osteoarthritis, live with a reduced quality of life. We are looking forward to the potential for a new treatment option and are excited to begin the Chondrograft™ study at DBJS,' states Dr. Joel Lobo. 'The results of this study could open up a new surgical option, that is minimally invasive to address this unmet clinical need.' Article content Throughout the clinical trial design and regulatory approval process, Nanochon was supported by HN Clinical Consulting (Missouri). 'Improving the lives of young adults and athletes by providing a solution to restore knee cartilage and hopefully help patients avoid costly knee replacement is a crucial therapy needed in the orthopedic world,' said Heather Neill, Founder and Principal. 'We appreciate Health Canada's thought-provoking questions throughout their review that helped us put forward the strongest application possible, which ultimately led to our approval.' HN Clinical Consulting will continue to support the full life cycle of Chondrograft™. Article content About HN Clinical Consulting Article content HN Clinical Consulting, LLC, brings a strategic focus to each project, keeping the goal of commercialization in sight. Building strong relationships with all stakeholders and maintaining a clinical strategic goal of project-oriented success to support long term Sponsor strategy/exit is key to development of clinical programs. The objective set is to stay ahead by planning for podium presence, publication, and reimbursement while designing the Clinical Investigational Plan. Article content Nanochon is a biotech and medical device company focused on developing innovative orthopedic solutions. Chondrograft™ is a minimally-invasive 3D printed implant that has allowed for immediate weight-bearing and motion in pre-clinical studies. The implant is based on research from the Tissue Engineering and Nanotechnology lab at the George Washington University, and is designed to integrate with healthy tissue over time, for maximum stability and benefit to the patient. Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care. Our mission is to develop a new approach to treat cartilage defects so that the hundreds of thousands of young, active patients with joint damage can return to their lifestyles without undergoing costly and invasive short-term fixes. Article content Article content Article content Article content
